BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 5, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2009

View Archived Issues

Snapshots of studies of CXA-101 presented at ICAAC: I

Read More

Anti-sclerostin antibody given with zoledronic acid efficacious in osteoporosis models

Read More

Fully human anti-DKK1 monoclonal antibody increases bone formation in osteopenia models

Read More

Synthetic pleuromutilin derivatives evaluated by Nabriva for the treatment of bacterial infections

Read More

LEAD Therapeutics discloses PARP inhibitors for cancer and other conditions

Read More

Allergan describes alpha2B-adrenoceptor agonists for pain and other conditions

Read More

Novel estrogen receptor beta agonists reported by Wyeth for the treatment of RA

Read More

Quidel cleared to add 2009 H1N1 influenza A virus reactivity to QuickVue package insert

Read More

Enzo Life Sciences introduces novel live-cell imaging kit for nuclear components

Read More

PF-04287881 shows potent in vitro and in vivo antibacterial activity in respiratory tract infections

Read More

S1P1 receptor agonists for the treatment of MS identified by GSK

Read More

AEterna Zentaris completes phase I oral AEZS-112 study in cancer

Read More

Stallergenes reports results of phase IIb/III trial of recombinant allergen of birch pollen

Read More

Enzo Biochem and NIH collaborate on autoimmune uveitis treatment

Read More

Maxygen confirms completion of joint venture with Astellas

Read More

Provectus completes treatment in phase II PV-10 trial for metastatic melanoma

Read More

Dor BioPharma receives NIH grant to develop thermostable vaccines

Read More

Cytokinetics presents progress and expansion of development programs

Read More

AMDL stockholders approve name change to Radient Pharmaceuticals

Read More

FDA grants priority review for Velcade-based therapy in multiple myeloma

Read More

AGI Therapeutics completes data analysis of phase III Rezular studies

Read More

King Pharmaceuticals launches Embeda for moderate to severe pain

Read More

Interim data from phase II trial of 5% Human Albumin Grifols in AD disclosed

Read More

Vitae initiates phase I renin inhibitor trial

Read More

Prolor Biotech commences phase I clinical trial for its long-acting growth hormone

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 5, 2025.
  • Art concept for medical research

    MicroRNAs in circulating extracellular vesicles as IPF biomarkers

    BioWorld Science
    MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Illustration of liver being targets with cross-hairs

    Study identifies CAND1 as therapeutic target in hepatoblastoma

    BioWorld Science
    Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing